Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Holding MIRM?
Track your performance easily
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.14 - $48.89
Previous Close$41.51
Volume1.19M
Average Volume (3M)379.04K
Market Cap
$1.99B
Enterprise Value$2.03B
Total Cash (Recent Filing)$284.44M
Total Debt (Recent Filing)$317.65M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Mar 05, 2025EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding48,004,582
10 Day Avg. Volume418,557
30 Day Avg. Volume379,035
Standard Deviation0.35
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)8.59
Price to Sales (P/S)6.49
Price to Cash Flow (P/CF)125.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.60
Enterprise Value/Gross Profit14.54
Enterprise Value/Ebitda-41.60
Forecast
1Y Price Target
$63.75Price Target Upside53.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Mirum Pharmaceuticals News
PremiumCompany Announcements
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth
Bulls Say, Bears Say
Bulls Say
Drug Development And Market PotentialVolixibat is seen as a potentially complementary therapy for patients on other treatments for PBC, offering further pruritus relief.
Earnings And Financial PerformanceMirum Pharmaceuticals remains on track to hit its 2024 revenue guidance of $310-$320M with several recent wins across its pipeline.
Regulatory MilestonesThe FDA has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis.
Bears Say
Product SafetyThe new label includes a warning to monitor for propylene glycol toxicity in younger patients.
Regulatory ApprovalsFailure to secure additional regulatory approvals for LIVMARLI.
Sales GrowthSales growth of LIVMARLI for ALGS and PFIC significantly below expectations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $48.89 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2025 which is in 73 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.149.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.3.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 48,004,580 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went up 1.61%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Mirum Pharmaceuticals Inc’s shares valued at 13M.
---
Mirum Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.75 (53.58% Upside)
$63.75 (53.58% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 71%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 137.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $117.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.81%
12-Months-Change
Fundamentals
Return on Equity
-38.83%
Trailing 12-Months
Asset Growth
2.65%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Company Deck
---
MIRM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive with significant revenue growth, new product developments, and financial milestones like positive cash flow. However, the company reported a net loss and high operating expenses, which are areas of concern.Read More>---
MIRM Stock 12 Month Forecast
Average Price Target
$63.75
▲(53.58% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Immunovant
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
30/33 ratings generated profit
1 Year Average Return
+34.13%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +34.13% per trade.
---